

Please type plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/809,631
Sheet 1 of 2				Filing Date	March 24, 2004
				First Named Inventor	Nathan Andrew Shapira
				Group Art Unit	1614
				Examiner Name	Unknown
				Attorney Docket Number	UF-368XC1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code* (if known)			
SW	U1	US 2002/103206	A1	Berendsen	08-01-2002	ALL
	U2					
	U3					
	U4					
	U5					
	U6					
	U7					
	U8					
	U9					
	U10					
	U11					
	U12					
	U13					
	U14					


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
SW	F1		NL 1014289	C	Waldinger <i>et al.</i>	08-07-2001	ALL	
SW	F2		WO 03/011340	A1	Wohlrab Johannes	02-13-2003	ALL	
SW	F3		WO 99/52517	A2	Sigma Tau Ind. Farmaceuti.	10-21-1999	ALL	
SW	F4		WO 00/23057	A2	Janssen Pharmaceutica N.V.	04-27-2000	ALL	
	F5							
	F6							
	F7							

Examiner Signature	SW	Date Considered	9/21/07
--------------------	----	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.




Please use a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/809,631		
		Filing Date	March 24, 2004		
		First Named Inventor	Nathan Andrew Shapira		
		Group Art Unit	1614		
		Examiner Name	Unknown		
Sheet		of		Attorney Docket Number	UF-368XC1

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SW	R1	KRISTIANSEN, KURT <i>et al.</i> , "Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT receptor interactions," <i>European Journal of Pharmacology</i> (1996), 306:195-210.	
	R2	LE WITT, PETER, "Hyperhidrosis and hypothermia responsive to oxybutynin," <i>Neurology</i> (1988), 38:506-507.	
	R3	LI, JAMES P. <i>et al.</i> , "Roles of 5-HT receptors in the release and action of secretion on pancreatic secretion in rats," <i>Am. J. Physiol.</i> (2001), 280:G595-G602.	
	R4	MARCY, R. <i>et al.</i> , "Anhidrotic Activity of Anti Cholinergics in Mice use of Different Routes of Administration," <i>Annales de Dermatologie et de Venereologie</i> (1977), 104:500-501.	
	R5	PASQUINI, M. <i>et al.</i> , "Mirtazapine for hyperhidrosis," <i>Psychosomatics</i> , United States (2003), 44(5):442-443.	
	R6	POMIER-LAYRARGUES, G. <i>et al.</i> , "Combined Treatment of Portal Hypertension with Ritanserin and Propranolol in Conscious and Unrestrained Cirrhotic Rats," <i>Hepatology</i> (1992), 15:878-882.	
	R7	SAADIA, DANIELA <i>et al.</i> , "Botulinum toxin type A in primary palmar hyperhidrosis: Randomized, single-blind, two-dose study," <i>Neurology</i> (2001), 57:2095-2099.	
	R8	SCHMIDT, ANNE W. <i>et al.</i> , "Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile," <i>European Journal of Pharmacology</i> (2001), 425:197-201.	
	R9	SEVILLE, R. H. <i>et al.</i> , "Treatment of Hyperhidrosis with Topical Propantheline -- a New Technique," <i>British Journal of Dermatology</i> (1972), 86:441.	
	R10	WILLIAMS, F. M. <i>et al.</i> , "Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers," <i>British Journal of Clinical Pharmacology</i> (1986), 22:301-308.	
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	8/21/07
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  Sheet 1 of 2		<b>Complete if Known</b>	
		Application Number	
		Filing Date	
		First Named Inventor	Shapira
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	UF-368X

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
SW	U1	US 4,062,848		van der Burg	12-13-1977	All
	U2	US 4,342,762		Budai <i>et al.</i>	08-03-1982	All
	U3	US 5,730,964		Waldstreicher	03-24-1998	All
	U4	US 6,420,541	B1	Behan <i>et al.</i>	07-16-2002	All
	U5	US 6,433,003	B1	Bobrove <i>et al.</i>	08-13-2002	All
SW	U6	US 6,455,567	B1	Monkhouse <i>et al.</i>	09-24-2002	All
	U7					
	U8					
	U9					
	U10					
	U11					
	U12					
	U13					
	U14					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
SW	F1	WO	98/17230	A2	Egis Gyogyszergyar RT	04-30-1998	All
	F2						
	F3						
	F4						
	F5						
	F6						
	F7						
	F8						
	F9						
	F10						

Examiner Signature		Date Considered	9/21/07
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number			
		Filing Date			
		First Named Inventor	Shapira		
		Group Art Unit			
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	UF-368X

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	ARROYO, HA <i>et al.</i> "A Syndrome of Hyperhidrosis, hypothermia, and bradycardia possibly due to central monoaminergic dysfunction," <i>Neurology</i> (March 1990), Volume 40 (3 Pt 1), pages 556-557.	
	R2	ARROYO, HA <i>et al.</i> "Episodic Spontaneous Hypothermia with Hyperhidrosis (Letters to the Editor)," <i>Pediatric Neurology</i> (1994), Volume 11, number 3, page 266.	
	R3	ASHTON, AK <i>et al.</i> "Cyproheptadine for drug-induced sweating (Letters to the Editor)," <i>American J. Psychiatry</i> (May 2002), Volume 159, number 5, pages 874-875.	
	R4	DAVIDSON, JR <i>et al.</i> "Hyperhidrosis in Social Anxiety Disorder," <i>Progress in Neuro-Psychopharmacology Biological Psychiatry</i> (December 2002), Volume 26, number 7-8, pages 1327-1331.	
	R5	SHETH, RD <i>et al.</i> "Episodic Spontaneous Hypothermia with Hyperhidrosis: Implication for Pathogenesis," <i>Pediatric Neurology</i> (1994), Volume 10, number 1, pages 58-60.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.